Novo Nordisk A/S buy melinda
Start price
27.03.18
/
50%
€39.35
Target price
24.07.18
€45.00
Performance (%)
10.39%
End price
24.07.18
€43.44
Summary
This prediction ended on 24.07.18 with a price of €43.44. The BUY prediction by melinda finished with a performance of 10.39%. melinda has a follow-up prediction for Novo Nordisk A/S where he still thinks Novo Nordisk A/S is a Buy. melinda has 50% into this predictionNovo Nordisk is a Danish pharmaceutical company that specializes in diabetes care and research. It is considered to be one of the largest companies in the world that focus exclusively on diabetes management, with a product portfolio that ranges from insulin treatment to obesity management. The company is listed on the Copenhagen Stock Exchange and has gained global recognition for its commitment to sustainable business practices and its contribution to diabetes research and treatment. Novo Nordisk has a strong financial track record and has consistently delivered solid returns to investors over the years.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Novo Nordisk A/S | - | - | - | - |
| iShares Core DAX® | 2.594% | -1.158% | 14.782% | 16.813% |
| iShares Nasdaq 100 | 3.553% | -1.727% | 43.265% | 44.227% |
| iShares Nikkei 225® | 0.687% | -8.354% | 18.454% | 1.361% |
| iShares S&P 500 | 2.209% | -0.942% | 31.361% | 42.812% |
Comments by melinda for this prediction
In the thread Novo Nordisk A/S diskutieren
SectorDrugProducts Agenda 02/05 Veröffentlichung der Ergebnisse
- Hemlibra, die Anti-Hämophilie-Droge der Roche AG, die Anti-HIV-Behandlung von Bikarvary, Gilead Sciences Inc. und die wöchentliche Diabetes-Behandlung von Novo Nordisk werden voraussichtlich bis 2022 einen Umsatz von 3 Milliarden US-Dollar übertreffen .
(Vom Mitglied beendet)
Current prediction by melinda for Novo Nordisk A/S
Novo Nordisk A/S
Start price
Target price
Perf. (%)
€147.92
08.06.23
08.06.23
€170.00
08.06.24
08.06.24
26.29%
12.09.23
12.09.23
